Best Practice & Research Clinical Haematology
Volume 21, Issue 2 , Pages 129-138 , June 2008

Vascular endothelium and graft-versus-host disease

  • Barbara C. Biedermann, MD (Chief of Molecular Medicine Section)

      Affiliations

    • Corresponding Author InformationTel.: +41 61 436 22 03; Fax: +41 61 436 36 70.

References 

  1. Bron D. Graft-versus-host disease. Current Opinion in Oncology. 1994;6(4):358–364
  2. Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. The New England Journal of Medicine. 1999;341(1):14–21
  3. Gratwohl A, Hermans J, Apperley J, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myelogenous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood. 1995;86(2):813–818
  4. Shlomchik WD. Graft-versus-host disease. Nature Reviews. Immunology. 2007;7(5):340–352
  5. Baird K, Pavletic SZ. Chronic graft versus host disease. Current Opinion in Hematology. 2006;13(6):426–435
  6. Mutis T, Gillespie G, Schrama E, et al. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nature Medicine. 1999;5(7):839–842
  7. Dickinson AM, Wang XN, Sviland L, et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nature Medicine. 2002;8(4):410–414
  8. Perruche S, Kleinclauss F, Tiberghien P, et al. B Cell allogeneic responses after hematopoietic cell transplantation: is it time to address this issue?. Transplantation. 2005;79(3 Suppl):S37–S39
  9. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. The American Journal of Medicine. 1980;69(2):204–217
  10. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295–304
  11. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. British Journal of Haematology. 1997;97(4):855–864
  12. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biology of Blood and Marrow Transplantation. 2005;11(12):945–956
  13. Starzl TE, Zinkernagel RM. Antigen localization and migration in immunity and tolerance. The New England Journal of Medicine. 1998;339(26):1905–1913
  14. Romanic AM, Graesser D, Baron JL, et al. T cell adhesion to endothelial cells and extracellular matrix is modulated upon transendothelial cell migration. Laboratory Investigation. 1997;76(1):11–23
  15. Meehan SM, McCluskey RT, Pascual M, et al. Cytotoxicity and apoptosis in human renal allografts: identification, distribution, and quantitation of cells with a cytotoxic granule protein GMP-17 (TIA-1) and cells with fragmented nuclear DNA. Laboratory Investigation. 1997;76(5):639–649
  16. van den Brink MR, Burakoff SJ. Cytolytic pathways in haematopoietic stem-cell transplantation. Nature Reviews. Immunology. 2002;2(4):273–281
  17. Pober JS. Warner-Lambert/Parke-Davis award lecture. Cytokine-mediated activation of vascular endothelium. Physiology and pathology. The American Journal of Pathology. 1988;133(3):426–433
  18. Pober JS, Gimbrone MA, Cotran RS, et al. Ia expression by vascular endothelium is inducible by activated T cells and by human gamma interferon. The Journal of Experimental Medicine. 1983;157(4):1339–1353
  19. Pober JS, Gimbrone MA. Expression of Ia-like antigens by human vascular endothelial cells is inducible in vitro: demonstration by monoclonal antibody binding and immunoprecipitation. Proceedings of the National Academy of Sciences of the United States of America. 1982;79(21):6641–6645
  20. Karmann K, Min W, Fanslow WC, et al. Activation and homologous desensitization of human endothelial cells by CD40 ligand, tumor necrosis factor, and interleukin 1. The Journal of Experimental Medicine. 1996;184(1):173–182
  21. Bevilacqua MP, Pober JS, Majeau GR, et al. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. The Journal of Experimental Medicine. 1984;160(2):618–623
  22. Slowik MR, Min W, Ardito T, et al. Evidence that tumor necrosis factor triggers apoptosis in human endothelial cells by interleukin-1-converting enzyme-like protease- dependent and -independent pathways. Laboratory Investigation. 1997;77(3):257–267
  23. Kummer M, Lev A, Reiter Y, et al. Vascular endothelial cells have impaired capacity to present immunodominant, antigenic peptides: a mechanism of cell type-specific immune escape. Journal of Immunology. 2005;174(4):1947–1953
  24. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney International. 1999;55(2):713–723
  25. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. The New England Journal of Medicine. 2006;355(10):1018–1028
  26. Dumler JS, Beschorner WE, Farmer ER, et al. Endothelial-cell injury in cutaneous acute graft-versus-host disease. The American Journal of Pathology. 1989;135(6):1097–1103
  27. Biedermann BC, Sahner S, Gregor M, et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet. 2002;359(9323):2078–2083
  28. Ertault-Daneshpouy M, Leboeuf C, Lemann M, et al. Pericapillary hemorrhage as criterion of severe human digestive graft-versus-host disease. Blood. 2004;103(12):4681–4684
  29. Deschaumes C, Verneuil L, Ertault-Daneshpouy M, et al. CD95 ligand-dependant endothelial cell death initiates oral mucosa damage in a murine model of acute graft versus host disease. Laboratory Investigation. 2007;87(5):417–429
  30. Murray AG, Petzelbauer P, Hughes CC, et al. Human T-cell-mediated destruction of allogeneic dermal microvessels in a severe combined immunodeficient mouse. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(19):9146–9150
  31. Soares MP, Lin Y, Sato K, et al. Accommodation. Immunology Today. 1999;20(10):434–437
  32. Lagaaij EL, Cramer-Knijnenburg GF, van Kemenade FJ, et al. Endothelial cell chimerism after renal transplantation and vascular rejection. Lancet. 2001;357(9249):33–37
  33. Shen N, Ffrench P, Guyotat D, et al. Expression of adhesion molecules in endothelial cells during allogeneic bone marrow transplantation. European Journal of Haematology. 1994;52(5):296–301
  34. Testa S, Manna A, Porcellini A, et al. Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation. Bone Marrow Transplantation. 1996;18(2):383–388
  35. Matsuda Y, Hara J, Osugi Y, et al. Serum levels of soluble adhesion molecules in stem cell transplantation-related complications. Bone Marrow Transplantation. 2001;27(9):977–982
  36. Chang DM, Wang CJ, Kuo SY, et al. Cell surface markers and circulating cytokines in graft versus host disease. Immunological Investigation. 1999;28(1):77–86
  37. Salat C, Holler E, Kolb HJ, et al. Endothelial cell markers in bone marrow transplant recipients with and without acute graft-versus-host disease. Bone Marrow Transplantation. 1997;19(9):909–914
  38. Biedermann BC, Tsakiris DA, Gregor M, et al. Combining altered levels of effector transcripts in circulating T cells with a marker of endothelial injury is specific for active graft-versus-host disease. Bone Marrow Transplantation. 2003;32(11):1077–1084
  39. Batts ED, Lazarus HM. Diagnosis and treatment of transplantation-associated thrombotic microangiopathy: real progress or are we still waiting?. Bone Marrow Transplantation. 2007;40(8):709–719
  40. Shulman H, Striker G, Deeg HJ, et al. Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury. The New England Journal of Medicine. 1981;305(23):1392–1395
  41. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplantation. 1994;14(4):495–504
  42. Martinez MT, Bucher C, Stussi G, et al. Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. Bone Marrow Transplantation. 2005;36(11):993–1000
  43. Holler E, Kolb HJ, Hiller E, et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood. 1989;73(7):2018–2024
  44. Senzolo M, Germani G, Cholongitas E, et al. Veno occlusive disease: update on clinical management. World J Gastroenterol. 2007;13(29):3918–3924
  45. Kumar S, DeLeve LD, Kamath PS, et al. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplation. Mago Clin Proc. 2003;78(5):589–598
  46. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Annals of Internal Medicine. 1993;118(4):255–267
  47. Tichelli A, Bucher C, Rovo A, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood. 2007;110(9):3463–3471
  48. Conen KL, Jeanneret C, Hecker B, et al. Acute occlusive large vessel disease leading to fatal stroke in a patient with systemic lupus erythematosus: arteritis or atherosclerosis?. Arthritis and Rheumatism. 2006;54(3):908–913
  49. Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood. 2007;109(4):1765–1772
  50. Kolodgie FD, Gold HK, Burke AP, et al. Intraplaque hemorrhage and progression of coronary atheroma. The New England Journal of Medicine. 2003;349(24):2316–2325
  51. Libby P, Pober JS. Chronic rejection. Immunity. 2001;14(4):387–397
  52. Richardson PG, Elias AD, Krishnan A, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998;92(3):737–744
  53. Chopra R, Eaton JD, Grassi A, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. British Journal of Haematology. 2000;111(4):1122–1129
  54. Au WY, Ma ES, Lee TL, et al. Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab. British Journal of Haematology. 2007;137(5):475–478
  55. Takatsuka H, Takemoto Y, Iwata N, et al. Oral eicosapentaenoic acid for complications of bone marrow transplantation. Bone Marrow Transplantation. 2001;28(8):769–774

PII: S1521-6926(08)00003-0

doi: 10.1016/j.beha.2008.02.003

Best Practice & Research Clinical Haematology
Volume 21, Issue 2 , Pages 129-138 , June 2008

Article Tools

* Image Usage & Resolution